Astrazeneca

FromAstraZeneca ([email protected])
Sent withMailchimp
Subject (150)Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that toz
Preheader (98)Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Typography
Arial
Colors
Text Analysis
Body Words162
Subject Words22
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px780 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight

Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that toz

Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials in patients with COPD
Positive high-level results from the Phase III OBERON and TITANIA trials in patients with chronic obstructive pulmonary disease (COPD) showed that toz